Your browser doesn't support javascript.
loading
[Coronary thrombosis: Physiopathology and treatment in the era of tailored medicine]. / Thrombose coronaire : physiopathologie et traitement à l'ère de la médecine personnalisée.
Zeitouni, M; Silvain, J; Kerneis, M; Guedeney, P; Overtchouk, P; Barthelemy, O; Hauguel-Moreau, M; Montalescot, G; Collet, J-P.
Affiliation
  • Zeitouni M; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Silvain J; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Kerneis M; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Guedeney P; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Overtchouk P; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Barthelemy O; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Hauguel-Moreau M; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Montalescot G; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
  • Collet JP; ACTION Study Group, Inserm UMRS 1166, institut de cardiologie, Sorbonne université, université Paris 06 (UPMC), hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: jean-philippe.collet@psl.aphp.fr.
Ann Cardiol Angeiol (Paris) ; 66(6): 373-379, 2017 Dec.
Article in Fr | MEDLINE | ID: mdl-29096907
ABSTRACT
Coronary thrombosis remains the leading cause for cardiovascular death in France. Great advances have been made in the knowledge of the basic mechanism involved in coronary thrombogenesis and in antithrombotic treatments. They have led to substantial survival benefit after myocardial infarction and enabled development of tailored therapeutic strategies, especially for high-risk patients. Direct oral anticoagulants have now entered the game for secondary prevention after coronary thrombosis.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Coronary Thrombosis / Integrative Medicine / Fibrinolytic Agents Type of study: Etiology_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: Fr Journal: Ann Cardiol Angeiol (Paris) Year: 2017 Document type: Article Affiliation country: Francia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Coronary Thrombosis / Integrative Medicine / Fibrinolytic Agents Type of study: Etiology_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: Fr Journal: Ann Cardiol Angeiol (Paris) Year: 2017 Document type: Article Affiliation country: Francia